Earnings Call · Q4 FY2022·2023-03-03

Q4 22EPS +33.33%·Rev n/aQ3 22EPS +17.31%·Rev n/aQ2 22EPS +19.15%·Rev n/aQ1 22EPS +35.00%·Rev n/a⚠ consensus missing

Inmune Bio, Inc. INMB

David Moss — Chief Financial Officer

RJ Tesi — Chief Executive Officer

CJ Barnum — Vice President of Neuroscience

Mark Lowdell — Immunopathologist / Executive

−4.1%1d on move date−4.2% vs SPY3d−9.8%5d−21.0%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more INMB calls or request research access.

More INMB calls Browse calls Request research access